Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 1
1949 1
1950 1
1953 4
1955 3
1958 1
1961 3
1962 3
1963 3
1964 7
1965 19
1966 23
1967 53
1968 65
1969 98
1970 112
1971 179
1972 263
1973 280
1974 319
1975 350
1976 268
1977 253
1978 230
1979 216
1980 211
1981 212
1982 295
1983 254
1984 361
1985 441
1986 385
1987 419
1988 319
1989 401
1990 365
1991 382
1992 412
1993 394
1994 321
1995 354
1996 370
1997 364
1998 348
1999 375
2000 369
2001 339
2002 375
2003 342
2004 360
2005 343
2006 363
2007 353
2008 386
2009 403
2010 449
2011 424
2012 464
2013 468
2014 498
2015 511
2016 470
2017 502
2018 547
2019 526
2020 526
2021 103
Text availability
Article attribute
Article type
Publication date

Search Results

17,824 results
Results by year
Filters applied: . Clear all
Page 1
Cytarabine and neurologic toxicity.
Baker WJ, Royer GL Jr, Weiss RB. Baker WJ, et al. J Clin Oncol. 1991 Apr;9(4):679-93. doi: 10.1200/JCO.1991.9.4.679. J Clin Oncol. 1991. PMID: 1648599 Review.
Cytarabine is an effective drug in the treatment of certain hematologic malignancies and its common toxicities are myelosuppression and gastrointestinal disturbance. In the past decade, neurotoxicity has been an increasingly recognized cytarabine effect. Intrathecal
Cytarabine is an effective drug in the treatment of certain hematologic malignancies and its common toxicities are myelosuppression a
Cytarabine.
Betcher DL, Burnham N. Betcher DL, et al. J Pediatr Oncol Nurs. 1990 Oct;7(4):154-7. doi: 10.1177/104345429000700406. J Pediatr Oncol Nurs. 1990. PMID: 2081008
Cytarabine is effective in the treatment of leukemias and CNS disease when given SQ, IM, IV, or intrathecally. Research is continuing to investigate high-dose therapy with cytarabine....
Cytarabine is effective in the treatment of leukemias and CNS disease when given SQ, IM, IV, or intrathecally. Research is continuing
[Cytarabine].
Ota K. Ota K. Gan To Kagaku Ryoho. 1987 Oct;14(10):2983-7. Gan To Kagaku Ryoho. 1987. PMID: 3478003 Japanese.
Cytarabine (ara-C) is the first line agent with its excellent activity for acute myelogenous leukemia. ...
Cytarabine (ara-C) is the first line agent with its excellent activity for acute myelogenous leukemia. ...
Clinical pharmacology of encapsulated sustained-release cytarabine.
Murry DJ, Blaney SM. Murry DJ, et al. Ann Pharmacother. 2000 Oct;34(10):1173-8. doi: 10.1345/aph.19347. Ann Pharmacother. 2000. PMID: 11054987 Review.
BACKGROUND: The therapeutic effectiveness of chemotherapy is often limited by the inability to sustain cytotoxic concentrations at the tumor site. Cytarabine liposome injection (DepoCyt), a sterile, injectable suspension of the antimetabolite cytarabine, encapsulate …
BACKGROUND: The therapeutic effectiveness of chemotherapy is often limited by the inability to sustain cytotoxic concentrations at the tumor …
Cytarabine (Cytosar).
[No authors listed] [No authors listed] Clin Pharmacol Ther. 1970 Jan-Feb;11(1):155-60. doi: 10.1002/cpt1970111155. Clin Pharmacol Ther. 1970. PMID: 5262667 No abstract available.
BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.
Zuckerman T, Ram R, Akria L, Koren-Michowitz M, Hoffman R, Henig I, Lavi N, Ofran Y, Horowitz NA, Nudelman O, Tavor S, Yeganeh S, Gengrinovitch S, Flaishon L, Tessler S, Ben Yakar R, Rowe JM. Zuckerman T, et al. Blood Adv. 2019 Nov 26;3(22):3740-3749. doi: 10.1182/bloodadvances.2019000468. Blood Adv. 2019. PMID: 31770437 Free PMC article. Clinical Trial.
High-dose cytarabine is the backbone of acute myeloid leukemia (AML) treatment. Nevertheless, its use in older patients is considerably limited due to increased toxicity. BST-236 (INN aspacytarabine) is a novel cytarabine prodrug designed to deliver high-dose cyt
High-dose cytarabine is the backbone of acute myeloid leukemia (AML) treatment. Nevertheless, its use in older patients is considerab …
New cytarabine analogs.
Capizzi RL. Capizzi RL. Bone Marrow Transplant. 1989 Jan;4 Suppl 1:43-5. Bone Marrow Transplant. 1989. PMID: 2713559 No abstract available.
Structural insights into mutagenicity of anticancer nucleoside analog cytarabine during replication by DNA polymerase eta.
Rechkoblit O, Johnson RE, Buku A, Prakash L, Prakash S, Aggarwal AK. Rechkoblit O, et al. Sci Rep. 2019 Nov 8;9(1):16400. doi: 10.1038/s41598-019-52703-7. Sci Rep. 2019. PMID: 31704958 Free PMC article.
Cytarabine (AraC) is the mainstay chemotherapy for acute myeloid leukemia (AML). ...
Cytarabine (AraC) is the mainstay chemotherapy for acute myeloid leukemia (AML). ...
Cerebrospinal fluid examination after liposomal cytarabine intrathecal injection.
Guillaume C, Vegas H, Pastuszka A, Le Brun C, Lanotte P. Guillaume C, et al. Ann Biol Clin (Paris). 2018 Oct 1;76(5):568-570. doi: 10.1684/abc.2018.1374. Ann Biol Clin (Paris). 2018. PMID: 30154068 English.
After discussion with the ordering physician, we learnt that the patient had received intrathecal liposomal cytarabine injection 19 days earlier. Cytarabine liposomes are spherules with a granular interior and range in size from 10-30 mum. ...Care needs to be taken …
After discussion with the ordering physician, we learnt that the patient had received intrathecal liposomal cytarabine injection 19 d …
17,824 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page